Allele specific repair of splicing mutations in cystic fibrosis through AsCas12a genome editing
暂无分享,去创建一个
Zeger Debyser | Marianne S Carlon | Anabela S Ramalho | A. Ramalho | A. Cereseto | M. Carlon | Z. Debyser | K. De Boeck | Kris De Boeck | Antonio Casini | Gianluca Petris | Claudia Montagna | Giulia Maule | Anna Cereseto | G. Petris | Antonio Casini | C. Montagna | G. Maule
[1] Jin-Soo Kim,et al. Genome-wide analysis reveals specificities of Cpf1 endonucleases in human cells , 2016, Nature Biotechnology.
[2] Karl Deisseroth,et al. Corrigendum: Ventral hippocampal afferents to the nucleus accumbens regulate susceptibility to depression , 2015, Nature Communications.
[3] L. Zentilin,et al. VSV-G-Enveloped Vesicles for Traceless Delivery of CRISPR-Cas9 , 2018, Molecular therapy. Nucleic acids.
[4] S. Birket,et al. Roadmap for an early gene therapy for cystic fibrosis airway disease , 2017, Prenatal diagnosis.
[5] P. Negulescu,et al. Correction of the F508del-CFTR protein processing defect in vitro by the investigational drug VX-809 , 2011, Proceedings of the National Academy of Sciences.
[6] C. Béroud,et al. Human Splicing Finder: an online bioinformatics tool to predict splicing signals , 2009, Nucleic acids research.
[7] L. Tsui,et al. Erratum: Identification of the Cystic Fibrosis Gene: Cloning and Characterization of Complementary DNA , 1989, Science.
[8] N. Gray,et al. Corrigendum: THZ1 targeting CDK7 suppresses STAT transcriptional activity and sensitizes T-cell lymphomas to BCL2 inhibitors , 2017, Nature Communications.
[9] Y. Kong,et al. Correction of F508del CFTR in airway epithelium using nanoparticles delivering triplex-forming PNAs , 2015, Nature communications.
[10] V. Baekelandt,et al. Immunological ignorance allows long-term gene expression after perinatal recombinant adeno-associated virus-mediated gene transfer to murine airways. , 2014, Human gene therapy.
[11] X. Estivill,et al. Cystic fibrosis patients with the 3272-26A>G splicing mutation have milder disease than F508del homozygotes: a large European study , 2001, Journal of medical genetics.
[12] Y. Kong,et al. Nanoparticles that deliver triplex-forming peptide nucleic acid molecules correct F508del CFTR in airway epithelium , 2015, Nature Communications.
[13] Hans Clevers,et al. Long-term expansion of epithelial organoids from human colon, adenoma, adenocarcinoma, and Barrett's epithelium. , 2011, Gastroenterology.
[14] B. van Steensel,et al. Easy quantitative assessment of genome editing by sequence trace decomposition , 2014, Nucleic acids research.
[15] Feng Zhang,et al. Engineered Cpf1 variants with altered PAM specificities increase genome targeting range , 2017, Nature Biotechnology.
[16] Nick Barker,et al. Organoids as an in vitro model of human development and disease , 2016, Nature Cell Biology.
[17] Charlie Huveneers,et al. How Close is too Close? The Effect of a Non-Lethal Electric Shark Deterrent on White Shark Behaviour , 2016, PloS one.
[18] Thomas Ferkol,et al. Repeated aerosolized AAV-CFTR for treatment of cystic fibrosis: a randomized placebo-controlled phase 2B trial. , 2007, Human gene therapy.
[19] A. Cereseto,et al. Reduction of HIV-1 Infectivity through Endoplasmic Reticulum-Associated Degradation-Mediated Env Depletion , 2014, Journal of Virology.
[20] Christopher B. Burge,et al. Maximum Entropy Modeling of Short Sequence Motifs with Applications to RNA Splicing Signals , 2004, J. Comput. Biol..
[21] David K. Gifford,et al. Predictable and precise template-free CRISPR editing of pathogenic variants , 2018, Nature.
[22] F. Pagani,et al. An exon-specific U1 small nuclear RNA (snRNA) strategy to correct splicing defects , 2012, Human molecular genetics.
[23] Meagan E. Sullender,et al. Optimized sgRNA design to maximize activity and minimize off-target effects of CRISPR-Cas9 , 2015, Nature Biotechnology.
[24] Hans Clevers,et al. A functional CFTR assay using primary cystic fibrosis intestinal organoids , 2013, Nature Medicine.
[25] B. Kerem,et al. Cellular and viral splicing factors can modify the splicing pattern of CFTR transcripts carrying splicing mutations. , 2000, Human molecular genetics.
[26] P. Harrison,et al. Cas9/gRNA targeted excision of cystic fibrosis-causing deep-intronic splicing mutations restores normal splicing of CFTR mRNA , 2017, PloS one.
[27] Hans Clevers,et al. Functional repair of CFTR by CRISPR/Cas9 in intestinal stem cell organoids of cystic fibrosis patients. , 2013, Cell stem cell.
[28] M. S. Chapman,et al. An essential receptor for adeno-associated virus infection , 2015, Nature.
[29] Sleiman Razzouk,et al. CRISPR‐Cas9: A cornerstone for the evolution of precision medicine , 2018, Annals of human genetics.
[30] M. Garcia-Blanco,et al. 5' exon replacement and repair by spliceosome-mediated RNA trans-splicing. , 2003, RNA.
[31] Francesca Baglio,et al. Comparing resting state fMRI de-noising approaches using multi- and single-echo acquisitions , 2017, PloS one.
[32] A. Doherty,et al. Preparation for a first-in-man lentivirus trial in patients with cystic fibrosis , 2016, Thorax.
[33] L. Tsui,et al. Identification of the cystic fibrosis gene: cloning and characterization of complementary DNA. , 1989, Science.
[34] J. Davies,et al. Genetic medicines for CF: Hype versus reality , 2016, Pediatric pulmonology.
[35] Antoine M. van Oijen,et al. Real-time single-molecule observation of rolling-circle DNA replication , 2009, Nucleic acids research.
[36] E. Buratti,et al. SR protein-mediated inhibition of CFTR exon 9 inclusion: molecular characterization of the intronic splicing silencer , 2007, Nucleic acids research.
[37] Jinglan Zhou,et al. Rescue of CF airway epithelial cell function in vitro by a CFTR potentiator, VX-770 , 2009, Proceedings of the National Academy of Sciences.
[38] A. López-Requena,et al. Engineered tobacco etch virus (TEV) protease active in the secretory pathway of mammalian cells. , 2015, Journal of biotechnology.
[39] R. Crystal,et al. Genetic Modification of the Lung Directed Toward Treatment of Human Disease. , 2017, Human gene therapy.
[40] M. Knowles,et al. Correction of Aberrant Splicing of the Cystic Fibrosis Transmembrane Conductance Regulator (CFTR) Gene by Antisense Oligonucleotides* , 1999, The Journal of Biological Chemistry.
[41] C. von Kalle,et al. Lentiviral Hematopoietic Stem Cell Gene Therapy Benefits Metachromatic Leukodystrophy , 2013, Science.
[42] D. C. Swarts,et al. Cas9 versus Cas12a/Cpf1: Structure–function comparisons and implications for genome editing , 2018, Wiley interdisciplinary reviews. RNA.
[43] M. van der Burg,et al. Targeted Genome Editing in Human Repopulating Hematopoietic Stem Cells , 2014, Nature.
[44] F. Demichelis,et al. Hit and go CAS9 delivered through a lentiviral based self-limiting circuit , 2017, Nature Communications.
[45] T. Blumenthal,et al. Trans‐splicing , 2011, Wiley interdisciplinary reviews. RNA.
[46] V. Baekelandt,et al. rAAV-CFTRΔR Rescues the Cystic Fibrosis Phenotype in Human Intestinal Organoids and Cystic Fibrosis Mice. , 2016, American journal of respiratory and critical care medicine.
[47] Johan Hofkens,et al. Super-resolution optical DNA Mapping via DNA methyltransferase-directed click chemistry , 2014, Nucleic acids research.
[48] Martin J. Aryee,et al. Genome-wide specificities of CRISPR-Cas Cpf1 nucleases in human cells , 2016, Nature Biotechnology.
[49] M. Rubin,et al. Inherited determinants of early recurrent somatic mutations in prostate cancer , 2017, Nature Communications.
[50] R. Ravazzolo,et al. Pharmacological Inhibition of the Ubiquitin Ligase RNF5 Rescues F508del-CFTR in Cystic Fibrosis Airway Epithelia. , 2018, Cell chemical biology.
[51] Richard L. Frock,et al. Genome-wide detection of DNA double-stranded breaks induced by engineered nucleases , 2014, Nature Biotechnology.
[52] H. Clevers,et al. Characterizing responses to CFTR-modulating drugs using rectal organoids derived from subjects with cystic fibrosis , 2016, Science Translational Medicine.
[53] P. McCray,et al. Lentiviral Vectors for the Treatment and Prevention of Cystic Fibrosis Lung Disease , 2019, Genes.
[54] T. Cooper. Use of minigene systems to dissect alternative splicing elements. , 2005, Methods.
[55] Garry R. Cutting,et al. Cystic fibrosis genetics: from molecular understanding to clinical application , 2014, Nature Reviews Genetics.
[56] J C Olsen,et al. A novel mutation in the cystic fibrosis gene in patients with pulmonary disease but normal sweat chloride concentrations. , 1994, The New England journal of medicine.
[57] Seng H. Cheng,et al. Organizing Section: Biochemistry/Molecular Biology Program Number: 4468 Poster Board Number: B0123 Presentation Time: 11:00 AM–12:45 PM CRISPR/Cas9-Mediated Genome Editing as a Therapeutic Approach for Leber Congenital Amaurosis 10 , 2017 .
[58] Brad T. Sherman,et al. Bioinformatics enrichment tools: paths toward the comprehensive functional analysis of large gene lists , 2008, Nucleic acids research.
[59] J. Puck,et al. Lentiviral Gene Therapy Combined with Low‐Dose Busulfan in Infants with SCID‐X1 , 2019, The New England journal of medicine.
[60] E. M. DeGennaro,et al. Multiplex gene editing by CRISPR-Cpf1 through autonomous processing of a single crRNA array , 2016, Nature Biotechnology.
[61] M. Amaral,et al. Cystic fibrosis patients with the 3272‐26A→G mutation have mild disease, leaky alternative mRNA splicing, and CFTR protein at the cell membrane , 1999, Human mutation.
[62] M. de Braekeleer,et al. The CFTR 3849+10kbC->T and 2789+5G->A alleles are associated with a mild CF phenotype , 2005, European Respiratory Journal.
[63] E. Caci,et al. In vitro Methods for the Development and Analysis of Human Primary Airway Epithelia , 2018, Front. Pharmacol..
[64] C. von Kalle,et al. Extensive methylation of promoter sequences silences lentiviral transgene expression during stem cell differentiation in vivo. , 2012, Molecular therapy : the journal of the American Society of Gene Therapy.
[65] Alessandro Romanel,et al. A highly specific SpCas9 variant is identified by in vivo screening in yeast , 2018, Nature Biotechnology.
[66] Gaurav Sahay,et al. Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis. , 2018, Molecular therapy : the journal of the American Society of Gene Therapy.
[67] Mauro Giacca,et al. Virus-mediated gene delivery for human gene therapy. , 2012, Journal of controlled release : official journal of the Controlled Release Society.
[68] A. May,et al. DNA Repair Profiling Reveals Nonrandom Outcomes at Cas9-Mediated Breaks. , 2016, Molecular cell.
[69] Nikhil T. Awatade,et al. Human Primary Epithelial Cell Models: Promising Tools in the Era of Cystic Fibrosis Personalized Medicine , 2018, Front. Pharmacol..
[70] Steve Cunningham,et al. Repeated nebulisation of non-viral CFTR gene therapy in patients with cystic fibrosis: a randomised, double-blind, placebo-controlled, phase 2b trial , 2015 .
[71] C. Higgins,et al. Increased persistence of lung gene expression using plasmids containing the ubiquitin C or elongation factor1α promoter , 2001, Gene Therapy.
[72] Nicholas A. Rossi,et al. Inference of CRISPR Edits from Sanger Trace Data , 2019, bioRxiv.
[73] R. Cimaz,et al. Drug Retention Rate and Predictive Factors of Drug Survival for Interleukin-1 Inhibitors in Systemic Juvenile Idiopathic Arthritis , 2019, Front. Pharmacol..
[74] T. Cathomen,et al. Targeted Integration of a Super-Exon into the CFTR Locus Leads to Functional Correction of a Cystic Fibrosis Cell Line Model , 2016, PloS one.
[75] Matthew C. Canver,et al. Analyzing CRISPR genome-editing experiments with CRISPResso , 2016, Nature Biotechnology.
[76] Jennifer A. Doudna,et al. CRISPR-Cas guides the future of genetic engineering , 2018, Science.
[77] Martin J. Aryee,et al. GUIDE-Seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases , 2014, Nature Biotechnology.
[78] Neville E. Sanjana,et al. Genome-Scale CRISPR-Cas9 Knockout Screening in Human Cells , 2014, Science.
[79] J. Manley,et al. hnRNP A1 functions with specificity in repression of SMN2 exon 7 splicing. , 2007, Human molecular genetics.
[80] Multiplex gene editing by CRISPR-Cpf1 through autonomous processing of a single crRNA array , 2016 .